ID
32391
Beschrijving
Safety and Efficacy of GMX1777 in the Treatment of Refractory Solid Tumors or Lymphomas; ODM derived from: https://clinicaltrials.gov/show/NCT00457574
Link
https://clinicaltrials.gov/show/NCT00457574
Trefwoorden
Versies (1)
- 29-10-18 29-10-18 -
Houder van rechten
See clinicaltrials.gov
Geüploaded op
29 oktober 2018
DOI
Voor een aanvraag inloggen.
Licentie
Creative Commons BY 4.0
Model Commentaren :
Hier kunt u commentaar leveren op het model. U kunt de tekstballonnen bij de itemgroepen en items gebruiken om er specifiek commentaar op te geven.
Itemgroep Commentaren voor :
Item Commentaren voor :
U moet ingelogd zijn om formulieren te downloaden. AUB inloggen of schrijf u gratis in.
Eligibility Solid Tumors and Lymphomas NCT00457574
Eligibility Solid Tumors and Lymphomas NCT00457574
- StudyEvent: Eligibility
Beschrijving
Exclusion Criteria
Alias
- UMLS CUI
- C0680251
Beschrijving
Pharmaceutical Preparations Other Cancer treatment | Cancer treatment Other
Datatype
boolean
Alias
- UMLS CUI [1,1]
- C0013227
- UMLS CUI [1,2]
- C0205394
- UMLS CUI [1,3]
- C0920425
- UMLS CUI [2,1]
- C0920425
- UMLS CUI [2,2]
- C0205394
Beschrijving
Exposure to GMX1777 | Exposure to GMX 1778
Datatype
boolean
Alias
- UMLS CUI [1,1]
- C0332157
- UMLS CUI [1,2]
- C2346839
- UMLS CUI [2,1]
- C0332157
- UMLS CUI [2,2]
- C2713488
Beschrijving
Comorbidity Uncontrolled
Datatype
boolean
Alias
- UMLS CUI [1,1]
- C0009488
- UMLS CUI [1,2]
- C0205318
Beschrijving
Pregnancy | Breast Feeding
Datatype
boolean
Alias
- UMLS CUI [1]
- C0032961
- UMLS CUI [2]
- C0006147
Similar models
Eligibility Solid Tumors and Lymphomas NCT00457574
- StudyEvent: Eligibility
C0024299 (UMLS CUI [2])
C0332197 (UMLS CUI [1,2])
C1514463 (UMLS CUI [1,3])
C0005953 (UMLS CUI [2,1])
C0031843 (UMLS CUI [2,2])
C0031328 (UMLS CUI [1,2])
C0205394 (UMLS CUI [1,2])
C0920425 (UMLS CUI [1,3])
C0920425 (UMLS CUI [2,1])
C0205394 (UMLS CUI [2,2])
C2346839 (UMLS CUI [1,2])
C0332157 (UMLS CUI [2,1])
C2713488 (UMLS CUI [2,2])
C0205318 (UMLS CUI [1,2])
C0006147 (UMLS CUI [2])
Geen commentaren